as 12-18-2024 10:38am EST
Harrow Inc is an eyecare pharmaceutical company engaged in the discovery, development, and commercialization of ophthalmic pharmaceutical products for the U.S. market. The company helps U.S. eyecare professionals preserve the gift of sight by making its comprehensive portfolio of prescription and non-prescription pharmaceutical products accessible and affordable to millions of Americans.
Founded: | 1998 | Country: | United States |
Employees: | N/A | City: | NASHVILLE |
Market Cap: | 1.9B | IPO Year: | N/A |
Target Price: | $55.00 | AVG Volume (30 days): | 369.6K |
Analyst Decision: | Strong Buy | Number of Analysts: | 4 |
Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
EPS: | -0.94 | EPS Growth: | N/A |
52 Week Low/High: | $9.13 - $59.23 | Next Earning Date: | 11-13-2024 |
Revenue: | $169,138,000 | Revenue Growth: | 48.15% |
Revenue Growth (this year): | 56.36% | Revenue Growth (next year): | 51.96% |
HROW Breaking Stock News: Dive into HROW Ticker-Specific Updates for Smart Investing
Simply Wall St.
23 days ago
Business Wire
a month ago
Business Wire
a month ago
Business Wire
a month ago
GuruFocus.com
a month ago
Business Wire
a month ago
GuruFocus.com
a month ago
Business Wire
a month ago
The information presented on this page, "HROW Harrow Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.